[P2–043]: COMPLEMENTARY EEG EVIDENCE FOR A SIGNIFICANTLY IMPROVED ALZHEIMER's DISEASE CASE AFTER PHOTOBIOMODULATION TREATMENT

Zomorrodi, Reza; Saltmarche, Anita; Loheswaran, Genane; Ho, Kai Fai; Lim, Lew

doi:10.1016/j.jalz.2017.06.691

Cited by 16 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides the improvement in cognitive abilities as assessed by the MMSE and Alzheimer's Disease Assessment Scale (ADAS-cog), increased sleep quality and decreased levels of anxiety, of anger outbursts, and of wandering were also observed. In another study (Zomorrodi et al, 2017), they reported that simultaneous application of transcranial and intranasal PBMT (810 nm, 40-Hz PW) for 6 days/week for 2 weeks resulted in a notable improvement of cognitive function in an AD patient as assessed with the MMSE and ADAS-cog scales as well as AD Cooperative Study-Activities of Daily Living Scale. These rapid cognitive enhancements were also accompanied by an overall increase in the absolute power of the EEG signal across all brain oscillations.…”

Section: Mild Cognitive Impairmentmentioning

confidence: 98%

Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review

Salehpour

Gholipour-Khalili

Farajdokht

et al. 2019

Reviews in the Neurosciences

View full text Add to dashboard Cite

The application of photobiomodulation therapy (PBMT) for neuronal stimulation is studied in different animal models and in humans, and has shown to improve cerebral metabolic activity and blood flow, and provide neuroprotection via anti-inflammatory and antioxidant pathways. Recently, intranasal PBMT (i-PBMT) has become an attractive and potential method for the treatment of brain conditions. Herein, we provide a summary of different intranasal light delivery approaches including a nostril-based portable method and implanted deep-nasal methods for the effective systemic or direct irradiation of the brain. Nostril-based i-PBMT devices are available, using either lasers or light emitting diodes (LEDs), and can be applied either alone or in combination to transcranial devices (the latter applied directly to the scalp) to treat a wide range of brain conditions such as mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease, cerebrovascular diseases, depression and anxiety as well as insomnia. Evidence shows that nostril-based i-PBMT improves blood rheology and cerebral blood flow, so that, without needing to puncture blood vessels, i-PBMT may have equivalent results to a peripheral intravenous laser irradiation procedure. Up to now, no studies were conducted to implant PBMT light sources deep within the nose in a clinical setting, but simulation studies suggest that deep-nasal PBMT via cribriform plate and sphenoid sinus might be an effective method to deliver light to the ventromedial part of the prefrontal and orbitofrontal cortex. Home-based i-PBMT, using inexpensive LED applicators, has potential as a novel approach for neurorehabilitation; comparative studies also testing sham, and transcranial PBMT are warranted.

show abstract

Section: Mild Cognitive Impairmentmentioning

confidence: 98%

Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review

Salehpour

Gholipour-Khalili

Farajdokht

et al. 2019

Reviews in the Neurosciences

View full text Add to dashboard Cite

show abstract

“…As stated by Hashmi et al in their article about the role of PBM in neurorehabilitation [20], transcranial PBM with low level red to NIR light had already been used on human subjects with moderate AD before the year 2010, although no peer reviewed publications existed as of then. This is slowly changing, with new devices being developed and more individuals being treated in pilot trials, confirming improvements in the Alzheimer's Disease Assessment Scale-cognitive and enhanced Neuropsychiatric Inventory scores, as well as an increase in regional cerebral blood flow and increased connectivity of the default mode network [29,[48][49][50][51][52][53].…”

Section: Applications Of Transcranial Photobiomodulation To Human Submentioning

confidence: 90%

Photobiomodulation for Alzheimer’s Disease: Translating Basic Research to Clinical Application

Enengl

Hamblin

Dungel

2020

JAD

View full text Add to dashboard Cite

One of the challenges in translating new therapeutic approaches to the patient bedside lies in bridging the gap between scientists who are conducting basic laboratory research and medical practitioners who are not exposed to highly specialized journals. This review covers the literature on photobiomodulation therapy as a novel approach to prevent and treat Alzheimer's disease, aiming to bridge that gap by gathering together the terms and technical specifications into a single concise suggestion for a treatment protocol. In light of the predicted doubling in the number of people affected by dementia and Alzheimer's disease within the next 30 years, a treatment option which has already shown promising results in cell culture studies and animal models, and whose safety has already been proven in humans, must not be left in the dark. This review covers the mechanistic action of photobiomodulation therapy against Alzheimer's disease at a cellular level. Safe and effective doses have been found in animal models, and the first human case studies have provided reasons to undertake large-scale clinical trials. A brief discussion of the minimally effective and maximum tolerated dose concludes this review, and provides the basis for a successful translation from bench to bedside.

show abstract

“…It presented even more significant cognitive improvement presenting more than 100% improvements in EEG measurements (Zomorrodi, Saltmarche, Loheswaran, Ho, & Lim, 2017).…”

Section: Eeg Data For a Significantlymentioning

confidence: 97%

Proceedings of the 2017 ISNR Conference: Poster Presentations

2017

View full text Add to dashboard Cite

Background and Description. Cardiorespiratory synchronization training (CRST) is a biofeedback intervention that uses slow and deep diaphragmatic breathing to increase autonomic activations, decrease symptoms of physical and mental disorders, and decrease negative emotions. Diaphragmatic breathing decreases central neuron system activations, increases the theta and alpha powers, and decreases the beta power of electroencephalography (EEG).High-technology mobile applications (APPs) combined with CRST brings innovation and convenience to users in the field of clinical psychological intervention. The aims of this study were to examine the effects of mobile APP for CRST on heart rate variability (HRV) and EEG.Method. Two hundred participants were recruited from a university and communities. Ninety-two healthy participants were screened and assigned randomly to the CRST group, relaxation training group (RT group as a sham-control group), and control (C) group.The CRST group received resonance frequency and diaphragmatic breathing training with an APP, and the RT group received muscle relaxation with normal breathing rate achieved by using an APP. The training program took 1 hour and was conducted weekly for 4 weeks. The C group did not undergo any APP training. All the participants underwent pretest and posttest measurements performed using psychological questionnaires, electrocardiography, and EEG. The raw electrocardiographic signals were transformed to HRV indexes, which included standard deviations of all normal-to-normal intervals (SDNN), low frequency (LF), high frequency (HF), total power, and maximum and minimum heart rate (HRmaxmin). The EEG parameters included absolute power and relative power of delta, low/high theta, low/high alpha, and low/high beta powers at Fz, Cz, Pz, F3, F4, C3, and C4.Results. The CRST group had significantly higher HRV indexes (including SDNN, LF, total power, and HRmax-min) than the RT and C groups; decreased relative high beta power at Pz, F4, C3, and C4; and increased absolute high alpha power at Pz. The CRST group also had a significantly higher increase in the change scores of HRV indexes ( SDNN, LF, total power, and HRmax-min) than the RT and C groups, increased absolute high alpha, and decreased relative high beta from pretest to posttest. Conclusion.Combining CRST with mobile APPs not only increased autonomic activations but also improved cortical activations. This program allows participants to practice everywhere and all the time and will be applied to different populations to improve autonomic dysregulation and cortical hyperarousal in the future. ReferencesChan, A. S., Cheung, M.-C., Sze, S. L., Leung, W.-M., & Shi, D. (2011 Background. Previous studies confirmed cortical hyperarousal at pre-sleep and sleep stages among patients with primary insomnia or major depressive disorder (MDD); few studies explored cortical hyperarousal at daytime.This study aims to investigate: (1) cortical hyperarousal at daytime among patient comorbid MDD and insomnia and (2) relationships b...

show abstract

[P2–043]: COMPLEMENTARY EEG EVIDENCE FOR A SIGNIFICANTLY IMPROVED ALZHEIMER's DISEASE CASE AFTER PHOTOBIOMODULATION TREATMENT

Cited by 16 publications

References 0 publications

Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review

Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review

Photobiomodulation for Alzheimer’s Disease: Translating Basic Research to Clinical Application

Proceedings of the 2017 ISNR Conference: Poster Presentations

Contact Info

Product

Resources

About